14-day Premium Trial Subscription Try For FreeTry Free
RSI low/high Values: [ 20 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of ALCLS.PA
Powered by GPT-4o
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Red day on Monday for Cellectis S.A. stock after losing 2.56%
(Updated on Jun 17, 2024)

Sell candidate since Jun 06, 2024 Loss -19.49% PDF

The Cellectis S.A. stock price fell by -2.56% on the last day (Monday, 17th Jun 2024) from 1.95€ to 1.90€. It has now fallen 6 days in a row. During the last trading day the stock fluctuated 4.41% from a day low at 1.86€ to a day high of 1.94€. The price has fallen in 8 of the last 10 days and is down by -21.33% for this period. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -144 thousand shares and in total, 135 thousand shares were bought and sold for approximately 256.02€ thousand.

Given the current short-term trend, the stock is expected to fall -2.56% during the next 3 months and, with a 90% probability hold a price between 1.85€ and 2.79€ at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

ALCLS.PA Signals & Forecast

There are few to no technical positive signals at the moment. The Cellectis S.A. stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at 2.14€ and 2.50€. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Monday, May 06, 2024, and so far it has fallen -34.60%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell along with the price during the last trading day, which is technical positive. One should, however, note that this stock may have low liquidity in periods, which increases the general risk.

Support, Risk & Stop-loss for Cellectis S.A. stock

There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.

This stock may move much during the day (volatility) and with periodic low trading volume this stock is considered to be "high risk". During the last day, the stock moved 0.0820€ between high and low, or 4.41%. For the last week the stock has had daily average volatility of 6.27%.

Cellectis S.A. is oversold on RSI14 (13). Some stocks may fall long and hard while being oversold on RSI, but stocks that are heavily oversold on RSI often pose good re-bounce chance and played well it can be a buy candidate.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (ALCLS.PA) For The Upcoming Trading Day Of Tuesday 18th

For the upcoming trading day on Tuesday, 18th we expect Cellectis S.A. to open at 1.90€, and during the day (based on 14 day Average True Range), to move between 1.78€ and 2.02€, which gives a possible trading interval of +/-0.118€ (+/-6.23%) up or down from last closing price. If Cellectis S.A. takes out the full calculated possible swing range there will be an estimated 12.46% move between the lowest and the highest trading price during the day.

With no support below and resistance from accumulated volume @ 1.95€, some 0.0500€ (2.63%) from the current price of 1.90€, our system finds the risk reward not very attractive.

Is Cellectis S.A. stock A Buy?

Cellectis S.A. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Current score: -4.872 Sell Candidate Unchanged

Predicted Opening Price for Cellectis S.A. of Tuesday, June 18, 2024

Fair opening price June 18, 2024 Current price
1.90€ ( 0.0351%) 1.90€

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for ALCLS.PA

Fibonacci Support & Resistance Levels

Level Price
R3 1.98 4.35%
R2 1.95 2.70%
R1 1.93 1.68%
Price 1.90
S1 1.87 -1.61%
S2 1.85 -2.63%
S3 1.82 -4.28%

Accumulated Volume Support & Resistance Levels

Level Price
R3 2.37 24.74%
R2 2.36 24.21%
R1 1.95 2.63%
Price 1.90
S1 0 -
S2 0 -
S3 0 -

FAQ

What is the symbol for Cellectis S.A. Stock and on which exchange is it traded?
The symbol for Cellectis S.A. is ALCLS.PA and it is traded on the PAR (Euronext Paris).

Should I buy or sell Cellectis S.A. Stock?
Cellectis S.A. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

How to buy Cellectis S.A. Stock?
Cellectis S.A. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Cellectis S.A. Stock.

What's the current price of Cellectis S.A. Stock?
As of the end of day on the Jun 17, 2024, the price of an Cellectis S.A. (ALCLS.PA) share was 1.90€.

What is the 52-week high and low for Cellectis S.A. Stock?
The 52-week high for Cellectis S.A. Stock is 3.44€ and the 52-week low is 0.89€.

What is the market capitalization of Cellectis S.A. Stock?
As of the Jun 17, 2024, the market capitalization of Cellectis S.A. is 136.327M.

When is the next earnings date for Cellectis S.A.?
The upcoming earnings date for Cellectis S.A. is Jun 27, 2025.
Click to get the best stock tips daily for free!

About Cellectis S.A.

Cellectis S.A. Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALL... ALCLS.PA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT